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INTRODUCTION
Drug-eluting stents (DES) were developed in an effort to
further reduce the rate of restenosis. Anti-restenotic drug (e.g.
sirolimus or paclitaxel) is released over a period as short as
days to as long as one year after implantation to reduce the
local proliferative healing response. Animal autopsy studies
suggested that DES affected re-endothelization, leading to
late thrombosis (1-4).
Delayed healing is associated with local and long-term
endothelial dysfunction and inflammation (5-8). Statins have
been shown to have pleiotropic effects apart from serum lipid-
lowering effect in human especially the effects in the vascu-
lar endothelium have been highlighted as the therapeutic
potential of statins (9). Furthermore, recent clinical data also
supported the early initiation of statin therapy in patients
with acute coronary syndromes (10-12). Previous studies have
shown that combined therapy with ezetimibe plus simvas-
tatin produced favorable effects on lipid levels and significant
reductions in C-reactive protein relative to statin monother-
apy (13, 14). We examined the neointima hyperplasia, endo-
thelization and arterial healing of ezetimibe/simvastatin after
DES implantation in a porcine coronary restenosis model.
MATERIALS AND METHODS
Animal study protocol
From January 2007 to March 2008, 23 female swines weigh-
ing 22-35 kg were studied in Animal Catherterization labo-
ratory of Chonnam National University Hospital in Gwangju,
Korea. The animal study was approved by the Institutional
Animal Care and Use Committee of the Chonnam National
716
Jung Sun Cho
1, Myung Ho Jeong
2, 
Doo Sun Sim
2, Young Joon Hong
2, 
Kyung Seob Lim
2, Jung Ha Kim
2, 
Hyoung Doo Kim
1, Ju Yeal Baek
1, 
Hee Jeoung Yoon
1, Sung-Ho Her
1, 
Seung Won Jin
1, Ju Han Kim
2, 
Youngkeun Ahn
2, Jeong Gwan Cho
2, 
Jong Chun Park
2, and Jung Chaee Kang
2
Department of Internal Medicine
1, The Catholic 
University of Korea College of Medicine, Seoul; The
Heart Center of Chonnam National University Hospital
2,
Chonnam National University Research Institute of
Medical Sciences, Gwangju, Korea
Address for Correspondence
Myung Ho Jeong, M.D.
Director of The Heart Research Center of Chonnam
National University Hospital Designated by Korea 
Ministry of Health, Welfare and Family Affairs, 
671 Jaebong-ro, Dong-gu, Gwangju 501-757, Korea
Tel : +82.62-220-6243, Fax : +82.62-228-7174
E-mail : myungho@chollian.net
This study was supported by a grant of the Korea
Healthcare Technology R&D project (A084869), 
Ministry for Health, Welfare & Family Affairs, Republic
of Korea.
J Korean Med Sci 2010; 25: 716-22 ISSN 1011-8934
DOI: 10.3346/jkms.2010.25.5.716
Effects of Combined Therapy with Ezetimibe Plus Simvastatin After
Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model
The aim of this study was to examine the anti-proliferative and anti-inflammatory
effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in
a porcine coronary restenosis model. Pigs were randomized into two groups in which
the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/
artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of
E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at
28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes.
Lymphohistiocyte count was not different between two groups (337±227 vs. 443±
366 cells, P=0.292), but neointima area was significantly smaller (1.00±0.49 mm
2
vs. 1.69±0.98 mm
2, P=0.021) and percent area stenosis was significantly lower
(23.3±10% vs. 39±19%, P=0.007) in E/S group compared with control group.
There were no significant differences in fibrin score (1.99±0.79 vs. 1.81±0.88, P=
0.49), endothelial score (1.75±0.66 vs. 1.80±0.59, P=0.79), and the percent of
endothelium covered lumen (43±21% vs. 45±21%, P=0.84) between E/S group
and control group. Combined therapy with ezetimibe and simvastatin inhibits neoin-
timal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing
after DES implantation in a porcine coronary restenosis model.
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University Hospital (CNU IACUC-H-2008-3).
To decrease acute thrombosis after stenting, premedication
with aspirin 100 mg and clopidogrel 75 mg per day was given
for 5 days before procedure. Statin group also was given eze-
timibe/simvastatin 10/20 mg before procedure and it was
maintained to 28 days after stenting, but control group was
not.
On the day of the stent implantation, pigs were anesthetized
with ketamine (20 mg/kg intramuscularly) and xylazine (2
mg/kg intramuscularly). They received 3 liters/min of sup-
plemental oxygen continuously through oxygen mask. After
subcutaneous lidocaine 2% at the cut-down site was admin-
istered, left carotid artery was surgically exposed, and a 7-8F
sheath was inserted. Continuous hemodynamic and electro-
cardiographic monitoring was maintained throughout the
procedure. After 10,000 uints of heparin was administered
intravenously as a bolus prior to the procedure, the target coro-
nary artery was engaged using standard 7-8F guiding catheters
and control angiograms of the left coronary arterie was per-
formed using nonionic contrast agent in two orthogonal views. 
Stent-induced coronary artery stenosis in porcine model
Pigs were randomized into two groups in which the coro-
nary arteries (23 pigs, 28 coronaries in ezetimibe/simvastatin
group, 15 coronaries in no ezetimibe/simvastatin group) had
either a sirolimus-eluting stent (SES) or paclitaxel-eluting
stent (PES) that was selected by random number generator.
Stents were deployed with oversizing (stent/artery ratio 1.3:1)
in porcine coronary arteries that was not different between
two groups. Fifteen pigs were taken 10/20 mg of ezetimibe/
simvastatin and 8 pigs were not taken ezetimibe/simvastatin.
The stent was deployed by inflating the balloon to nominal
pressure at injury site and the resulting stent to artery ratio
was 1.3:1. Coronary angiograms were obtained immediately
after stent implantation. Equipment was removed and the
carotid artery was ligated. All animals received 100 mg of
aspirin and 75 mg of clopidogrel orally daily until sacrifice.
At 28 days after stenting, animals underwent coronary angiog-
raphy in the same orthogonal views before sacrifice and 20
mL of potassium chloride intracoronary injection was done.
The hearts were removed, and the coronary arteries were pres-
sure-perfusion fixed at 70 mmHg in 10% neutral buffered
formalin overnight. Arteries were step-sectioned, processed
routinely for light microscopy, and stained with hematoxylin-
eosin stain for histological analysis. 
Histopathological analysis 
Histopathologic evaluation of each artery was blindly per-
formed by an experienced cardiovascular pathologist. The
specimens were embedded in methylmethacrylate and sec-
tions were cut with the low speed diamond wafer mounted
to the Buehler Isomet saw (Buehler Ltd., IL, USA), leaving
the stent wires intact in the cross sections to minimize poten-
tial artifacts from removal of stent wires. Fifty to 100 mm sec-
tions were obtained at about 1 mm apart and stained with
hematoxylin-eosin for histological analysis with grinding
method. Also, the specimens were stained with Carstair’s
fibrin stain for determining delayed arterial healing accord-
ing to discriminate fibrin score. The quantitative analysis
included the cross-sectional areas of the external elastic lam-
ina (EEL), internal elastic lamina (IEL), and lumen of each
stented section, and the lumen area of each non-stented sec-
tions, measured with a calibrated microscope, digital video
imaging system, and microcomputer program (Visus 2000
Visual Image Analysis System). Neointimal thickness was
measured as the distance from the inner surface of each stent
strut to the luminal border. From the measured data, the fol-
lowing parameters were calculated: percentage area stenosis
(%AS) ([neointimal area/IEL area]×1,000) (15-19). Select-
ed case were stained by CD31 immunohistochemistry stain
for confirming evaluation of endothelialization.
Evaluation of arterial injury, fibrin scores, endothelization
scores, inflammatory cells
Arterial injury at each strut site was determined by the
anatomic structures penetrated by each strut. A numeric value
was assigned, as previously described by Schwartz et al.: 0=
IEL intact; 1=IEL lacerated; 2=IEL and media lacerated, EEL
not lacerated; 3=EEL lacerated, stent strut may extend into
the adventitia. The injury score for the vessel section is cal-
culated as dividing the sum of injury scores by the total num-
ber of struts (18, 19). Total cells and inflammatory cells which
were mostly lymphohistiocytes otherwise eosinophils, giant
cells were counted. The histomorphometric parameters mea-
sured on 5 or 6 sections per vessel were averaged and expressed
as mean value±standard error. Ordinal data for fibrin were
collected on each stent section using a scale of 0 to 3 as pre-
IEL, internal elastic lamina; NS, not significant; DES, drug eluting stent.
Ezetimibe 
plus simvastatin
(n=28)
Variables
Control 
(n=15)
P value
Types of DES 
Sirolimus-eluting stent 14 8 NS
Paclitaxel-eluting stent 14 7 NS
IEL area (mm
2)4 . 4 2 ±0.8 4.30±1.0 NS
Lumen area (mm
2)3 . 4 2 ±0.9 2.61±1.0 0.013
Neointima area (mm
2)1 . 0 0 ±0.4 1.69±0.9 0.021
Area stenosis (%) 23.5±10.3 39.4±19.1 0.007
Inflammatory cell (%) 5.20±2.7 5.57±4.0 NS
Injury score 1.40±0.2 1.38±0.2 NS
Endothelial score 1.75±0.6 1.80±0.59 NS
Endothelized lumen (%) 43.70±21.1 45.06±21.9 NS
Table 1. Coronary artery morphometric measurements in stented
vessels according to medication of ezetimibe plus simvastatin718 J.S. Cho, M.H. Jeong, D.S. Sim, et al.
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Fig. 1. Neointima area was significantly smaller (A) and percent area stenosis was significantly lower (B) in ezetimibe/simvastatin group
compared with control group.
B A
Fig. 2. Drug-eluting stented porcine coronary arteries (Methyl methacrylate staining: ×25, A, B and ×100, C, D). Neointima area was larg-
er and percent area stenosis was higher in control group compared with ezetimibe/simvastatin group.
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viously reported (17). The endothelization score was defined
as the extent of the circumference of the arterial lumen cov-
ered by endothelium and was scored form 1 to 3: 1 <25%;
2 25-75%; 3 >75% (19).
Statistical analysis 
Statistical analysis was performed using the commercially
available software (SPSS Version 15, Chicago, IL, USA). The
data are presented as mean value±SD. Unpaired Student’s
t test was used for the comparison of inflammatory cell counts
normalized to injury score of the two stent groups. To examine
the correlations between the measured histologic variables,
regression analysis was applied for each set of measured vari-
ables. A value of P<0.05 was considered statistically signifi-
cant.
RESULTS
One pig of ezetimibe/simvastatin group died before 28
days, one coronary artery of one pig of no ezetimibe/simvas-
tatin group could not be engaged guiding catheter. There-
fore, 28 coronaries in ezetimibe/simvastatin group and 15
coronaries in no ezetimibe/simvastatin group was analyzed.
The types of DES were not different between two groups
(Table 1). 
In neointima, most inflammatory cells were lymphohisti-
ocytes. Lymphohistiocyte count was not different between
two groups (337±227 cells vs. 443±366 cells, P=0.292).
Furthermore, the percent of inflammatory cell among the
total cell in neointima was not different between two groups
(5.2±2.77% vs. 5.57±4.0%, P=0.73). Neointima area was
significantly smaller (1.00±0.49 mm2 vs. 1.69±0.98 mm2,
P=0.021) and percent area stenosis was significantly lower
(23.3±10% vs. 39±19%, P=0.007) in ezetimibe/simvas-
tatin group compared with control group (Figs. 1, 2).
There was no significant differences in fibrin score (1.99±
0.79 vs. 1.81±0.88, P=0.49), endothelial score (1.75±0.66
vs. 1.80±0.59, P=0.79), and the percent of endothelium cov-
ered lumen (43±21% vs. 45±21%, P=0.84) between eze-
timibe/simvastatin group and control group (Table 1, Figs.
3, 4).
DISCUSSION
In our study, combined therapy with ezetimibe and sim-
vastatin may inhibit neointimal hyperplasia, and that result
may be related with effects of ezetimibe in animal study (26).
Furthermore, we evaluated for inflammatory reaction, reen-
dothelization, and arterial healing, but there are no signifi-
cant differences between two groups. These results suggest-
ed ezetimibe and simvastatin prevent the neointima hyper-
plasia, but does not promote arterial healing for preventing
late stent thrombosis.
In DES period, main concern about the DES was divided
to ISR by intimal hyperplasia and late stent thrombosis by
delayed arterial healing (21-23). In this aspect, statin could
be expected to have therapeutic potential in the both aspects.
Endothelium is a single layer of endothelial cells lining the
vascular wall and plays an integral part in maintaining vas-
cular homeostasis. However, stenting causes significant injury
to the vascular wall and endothelium resulting in inflamma-
Fig. 3. Carstair’s fibrin stain (×200) for determining delayed arterial healing according to discriminate fibrin score that is not different bet-
ween ezetimibe/simvastatin (A) and (B) control groups.
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tion, repair and the development of neointimal hyperplasia.
Hastening the natural process of repair has potentially bene-
fit of reducing the amount of neointimal hyperplasia and stent
thrombosis. 
The cholesterol-independent pleiotropic effect of statin has
been proved, especially the effects in the vascular endotheli-
um have been highlighted as the therapeutic potential of
statins. The mechanisms of pleiotropic effects in the vascu-
lar endothelium of statin without changes in serum choles-
terol levels was not proved clearly. However, inhibition of
Rho and Rho kinase activity and stimulation the PI3 kinase/
Akt pathway may lead to increased in endothelial nitric oxide
synthase (eNOS) expression and activation was considered
one of the mechanisms (28-30). Statin is identified as agents
that augment the mobilization and recruitment of endothe-
lial progenitor cell (EPC) to the injured area (24). EPC mobi-
lization from bone marrow by statins may contribute to reen-
dothelization or angiogenesis. eNOS, vascular endothelial
growth factor (VEGF), and adhesion molecules mediate statin-
induced EPC recruitment and activation in deendothelized
vascular wall. Also, other mechanisms of pleiotropic effects
in the vascular smooth muscle cell of statin were suggested;
statin modulates phenotypic changes of vascular smooth mus-
cle cell (VSMC) and subsequently their proliferation and mig-
ration. 
Statins also have been shown to reduce the number of in-
flammatory cells in atherosclerotic lesions. Recent reports
have shown the inhibitory effects of statins on adhesion mole-
cules such as intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule (VCAM-1) and E-selectin,
which are involved in the adhesion, rolling, extravasation of
inflammatory cells. However, the effect of statins on vascu-
lar inflammation mediated by adhesion molecules is still con-
troversial (9). In our study, numbers of migrated inflamma-
tory cells in neointima were not different between two groups. 
Several animal studies indicated that neointimal hyper-
plasia and inflammation in stented vessels can be reduced
by statin both in hypercholesterolemic animals and in ani-
mals with normal lipid levels (20, 28-30). However, in nor-
mocholesterolemic patients undergoing coronary stenting,
simvastatin does not prevent intimal hyperplasia or in-stent
restenosis, but it promotes atherosclerotic regression both at
stented and at non-stented sites. The above result was not
based on histopathologic analysis but intravascular ultrasound
analysis that can cause different result from animal studies
(23).
Ezetimibe is a novel agent that potentially inhibits the in-
testinal absorption of cholesterol by blocking the Niemann-
Pick C1-like 1 protein for cholesterol transport across the
intestinal wall (14, 25-27). Combined therapy with ezetim-
ibe plus simvastatin produced favorable effects on blood lipid
levels and significant reductions in C-reactive protein com-
pared with statin monotherapy (13, 14).
In our porcine model, combined therapy with ezetimibe
plus simvastatin inhibits neointimal hyperplasia, but does
not inhibit inflammatory infiltration and arterial healing after
DES implantation in a porcine coronary restenosis model.
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